Liquidators can face significant issues when appointed over
companies that operate under the licencing regime of the
Therapeutic Goods Administration (TGA).
The TGA is a Commonwealth Government agency administered by the
Department of Health. It's responsible for regulating the
supply, import, export, manufacturing and advertising of
therapeutic goods – which can range from biological products
(like stem cells and cord blood) to medical devices (such as blood
pressure monitors and MRI scanners).1 It also issues
licences to companies that handle therapeutic goods.
The TGA operates in accordance with the Therapeutic Goods
Act 1989 (Cth) (the Act) and the accompanying Therapeutic
Goods Regulations 1990 (Cth) (the Regulations). The Act
provides for controls relating to the quality, safety, efficacy and
availability of therapeutic goods produced or used with
Australia.2
